ClinicalTrials.gg
RecruitingNCT06588478Updated Nov 4, 2026

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 2 interventional study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Loxo Oncology, Inc.. Recruiting at 129 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 4, 2026Site recruiting status changed2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
8th of 23
249 · median 87
Started
2025
with 6 others
Phase 2
11 of 23
7 open now
Primary completion
2028-06
later than 9 of 18 live
Registered
12th of 23
by date
Lead sponsor
6 of 23
Loxo Oncology, Inc.

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 8th largest by planned enrollment, is one of 7 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 9 of the 18 other live ones, and was the 12th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed diagnosis of CLL/SLL as defined by iwCLL 2018 criteria.
  • Part 1: Have received prior CLL/SLL treatment
  • Have received at least 1, but not more than 3 for CLL/SLL
  • Have received a covalent BTK inhibitor
  • Part 2: Have received no prior treatment for CLL/SLL

    • Part 1 - Known 17p deletion status (positive or negative)
    • Part 2 - Must have 17p deletion (positive)
  • Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy
  • Capable of swallowing oral study medication.
  • Have an Performance Status (ECOG) score of 0 to 2.

Exclusion criteria

Exclusion Criteria:

  • Have received prior treatment with a BTK degrader or a noncovalent BTK inhibitor
  • Have a history of greater than or equal to (>=) Grade 3 bleeding due to treatment with a BTK inhibitor
  • Have known or suspected Richter's transformation
  • Have known or suspected history of central nervous system involvement by CLL/SLL
  • Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:

    • nonmelanoma skin cancer or lentigo malignant melanoma
    • cervical carcinoma in situ
    • localized prostate cancer undergoing active surveillance, and
    • localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. Individual may be receiving hormonal therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
249 participants (estimated)

Study arms

  • Active comparator
    Pirtobrutinib Standard Dose (Dose 1)-Part 1

    Pirtobrutinib administered orally.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib Dose 2-Part 1

    Pirtobrutinib administered orally.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib Dose 3-Part 1

    Pirtobrutinib administered orally.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib Standard Dose-Part 2

    Pirtobrutinib administered orally.

    Drug: Pirtobrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate is defined as the proportion of participants who achieve the best overall response at or before the initiation of subsequent anticancer therapy of CR, CRi, nPR, or PR. ORR will be assessed using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 response criteria.

    Time frame: Baseline up to 3 years

Secondary outcomes

  1. Duration of Response

    Duration of response is defined as the time from the date of the first documented CR, CRi, nPR, or PR to disease progression (per iwCLL 2018) or death from any cause.

    Time frame: Baseline up to 3 years

07

Study locations

125 of 129 sites recruiting
  • Ironwood Cancer & Research Centers
    Chandler, Arizona 85224, United States
    Recruiting
    • Michael Musci · Principal investigator
  • City of Hope National Medical Center
    Duarte, California 91010, United States
    Recruiting
    • · Contact800-826-4673
    • Alexey Danilov · Principal investigator
  • City of Hope National Medical Center
    Irvine, California 92618, United States
    Recruiting
    • · Contact626-218-2405
    • Alexey Danilov · Principal investigator
  • Palo Alto Medical Foundation Research Institute (PAMFRI)
    Palo Alto, California 94304, United States
    Recruiting
    • Roozbeh Mohajer · Principal investigator
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
    Recruiting
    • Bita Fakhri · Principal investigator
  • Rocky Mountain Cancer Center
    Aurora, Colorado 80012, United States
    Recruiting
    • · Contact303-418-7639
    • John Burke · Principal investigator
  • University of Miami Hospital and Clinics, Sylvester Cancer Center
    Miami, Florida 33136, United States
    Recruiting
    • Alvaro Alencar · Principal investigator
  • City of Hope National Medical Center, Atlanta Cancer Center
    Newnan, Georgia 30265, United States
    Recruiting
    • Sabarish Ayyappan · Principal investigator
  • Mission Cancer + Blood
    Waukee, Iowa 50263, United States
    Recruiting
    • · Contact515-282-2921
    • Tara Graff · Principal investigator
  • Saint Elizabeth Medical Center Edgewood
    Edgewood, Kentucky 41017, United States
    Recruiting
    • Miguel Islas-Ohlmayer · Principal investigator
  • American Oncology Partners, PA
    Bethesda, Maryland 20817, United States
    Recruiting
    • · Contact301-571-2016
    • Victor Priego · Principal investigator
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
    Recruiting
    • Andrew Wilks · Principal investigator
  • Gulfport Memorial Hospital
    Gulfport, Mississippi 39501, United States
    Recruiting
    • · Contact228-575-1234
    • Pamela Tuli · Principal investigator
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89074, United States
    Recruiting
    • Anthony Nguyen · Principal investigator
  • East Carolina University
    Greenville, North Carolina 27834, United States
    Recruiting
    • · Contact252-744-1015
    • Darla Liles · Principal investigator
  • Williamette Valley Cancer Institute & Research Center
    Eugene, Oregon 97401, United States
    Recruiting
    • · Contact541-683-5001
    • Jeff Sharman · Principal investigator
  • Cancer Care Associates Of York
    York, Pennsylvania 17403, United States
    Recruiting
    • · Contact717-741-9229
    • Jackson Gao · Principal investigator
  • USO-Texas Oncology-Central/South Texas
    Austin, Texas 78705, United States
    Recruiting
    • · Contact512-421-4100
    • Jason Melear · Principal investigator
  • Sarah Cannon Research Institute/SCRI
    The Woodlands, Texas 77380, United States
    Recruiting
    • · Contact999-999-9999
    • SMO Sarah Cannon Research Inst. · Principal investigator
  • USO-Virginia Oncology Associates
    Hampton, Virginia 23666, United States
    Recruiting
    • · Contact757-368-0437
    • Celesteann Bremer · Principal investigator
  • Flinders Medical Centre
    Adelaide, 5042, Australia
    Recruiting
    • Kate Manos · Principal investigator
  • Bankstown-Lidcombe Hospital
    Bankstown, 2200, Australia
    Recruiting
    • Adrian Yeung · Principal investigator
  • Box Hill Hospital
    Box Hill, 3128, Australia
    Recruiting
    • Ahmad Zargari · Principal investigator
  • Coffs Harbour Health Campus
    Coffs Harbour, 2450, Australia
    Recruiting
    • Kyle Crassini · Principal investigator
  • Royal Hobart Hospital
    Hobart, 7000, Australia
    Recruiting
    • · Contact61 3 6166 6655
    • Rosemary Harrup · Principal investigator
  • ICON Cancer Centre - Kurralta Park
    Kurralta Park, 5037, Australia
    Recruiting
    • Ka Chun Cheung · Principal investigator
  • Latrobe Regional Health
    Traralgon, 3844, Australia
    Recruiting
    • Michael Ashby · Principal investigator
  • Calvary Mater Newcastle
    Waratah, 2298, Australia
    Recruiting
    • · Contact0240143021
    • Alex Holmes · Principal investigator
  • The Perth Blood Institute - West Perth
    West Perth, 6005, Australia
    Recruiting
    • Ross Baker · Principal investigator
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
    Recruiting
    • Sasanka Handunnetti · Principal investigator
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
    Recruiting
    • Virginie De Wilde · Principal investigator
  • AZ Sint-Jan Brugge-Oostende AV
    Bruges, 8000, Belgium
    Recruiting
    • · Contact3250452320
    • Sylvia Snauwaert · Principal investigator
  • UZ Gent
    Ghent, 9000, Belgium
    Recruiting
    • · Contact+32 9 332 21 25
    • Fritz Offner · Principal investigator
  • Groupe Jolimont
    La Louvière, 7100, Belgium
    Recruiting
    • VANESSA DELRIEU · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Ann Janssens · Principal investigator
  • Clinique Saint Pierre
    Ottignies, 1340, Belgium
    Recruiting
    • Thierry Connerotte · Principal investigator
  • AZ Delta vzw
    Roeselare, 8800, Belgium
    Recruiting
    • · Contact003251237322
    • Lien Deleu · Principal investigator
  • AZ Nikolaas
    Sint-Niklaas, B-9100, Belgium
    Recruiting
    • Vanessa Van Hende · Principal investigator
  • CHR Verviers - La Tourelle
    Verviers, 4800, Belgium
    Recruiting
    • · Contact087219418
    • Gaetan Vanstraelen · Principal investigator
  • Royal Victoria Regional Health Centre
    Barrie, L4M 6M2, Canada
    Recruiting
    • Derek Nay · Principal investigator
  • Saskatoon Cancer Centre
    Saskatoon, S7N4H4, Canada
    Recruiting
    • Julie Stakiw · Principal investigator
  • Fakultní nemocnice Brno Bohunice
    Brno, 625 00, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
    Completed

    Not enrolling at this site — choose another above.

  • Vseobecna fakultni nemocnice v Praze
    Prague, 12808, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Aarhus Universitetshospital, Skejby
    Aarhus, 8200, Denmark
    Recruiting
    • Hans Bentzen · Principal investigator
  • Odense Universitetshospital
    Odense, 5000, Denmark
    Recruiting
    • Annika Rewes · Principal investigator
  • Centre Hospitalier d'Argenteuil Victor Dupouy
    Argenteuil, 95107, France
    Recruiting
    • driss chaoui · Principal investigator
  • Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre
    Caen, 14033, France
    Recruiting
    • Baptiste DELAPIERRE · Principal investigator
  • Centre Hospitalier du Mans
    Le Mans, 72000, France
    Recruiting
    • · Contact+33255463467
    • Kamel Laribi · Principal investigator
  • Groupe Hospitalier de la Région de Mulhouse et Sud Alsace - Hôpital Emile Muller
    Mulhouse, 68100, France
    Recruiting
    • Bernard Drenou · Principal investigator
  • Centre Antoine-Lacassagne
    Nice, 06189, France
    Recruiting
    • Luca INCHIAPPA · Principal investigator
  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau
    Tours, 37044 Cedex 9, France
    Recruiting
    • Caroline Dartigeas · Principal investigator
  • MV-Zentrum für Onkologie und Hämatologie
    Cologne, 50677, Germany
    Recruiting
    • Jan-Phillip Weber · Principal investigator
  • Centrum für Hämatologie und Onkologie Bethanien
    Frankfurt, 60389, Germany
    Recruiting
    • · Contact00496956005621
    • Christian Schmitt · Principal investigator
  • OSP Göttingen
    Göttingen, 37073, Germany
    Recruiting
    • · Contact0049551488795915
    • Michael Metz · Principal investigator
  • Onkologisches Ambulanzzentrum Hannover
    Hanover, 30171, Germany
    Recruiting
    • · Contact004989979680
    • Michael Gärtner · Principal investigator
  • Klinikum Aschaffenburg-Alzenau
    Hösbach, 63768, Germany
    Recruiting
    • · Contact0049 60214527391
    • Manfred Welslau · Principal investigator
  • InVO Institut für Versorgungsforschung in der Onkologie
    Koblenz, 56068, Germany
    Recruiting
    • · Contact49 261 921 5693-0
    • Rudolf Weide · Principal investigator
  • Evangelismos General Hospital of Athens
    Athens, 106 76, Greece
    Recruiting
    • · Contact+302107201721
    • Maria Bouzani · Principal investigator
  • Attikon General University Hospital
    Chaïdári, 12462, Greece
    Recruiting
    • · Contact0030 2105832307
    • Vasiliki Pappa · Principal investigator
  • G. Papanikolaou General Hospital
    Thessaloniki, 570 10, Greece
    Recruiting
    • · Contact+302313307533
    • Niki Stavroyianni · Principal investigator
  • General Hospital of Athens "Laiko"
    Αthens, 11526, Greece
    Recruiting
    • Theodoros Vassilakopoulos · Principal investigator
  • Semmelweis Egyetem
    Budapest, 1088, Hungary
    Recruiting
    • · Contact36208258660
    • ZSOLT GYORGY Nagy · Principal investigator
  • Dél-Pesti Centrumkórház
    Budapest, 1097, Hungary
    Recruiting
    • · Contact+3630 455 8218
    • Zoltan Matrai · Principal investigator
  • Pécsi Tudományegyetem Klinikai Központ
    Pécs, 7624, Hungary
    Recruiting
    • · Contact+36 72 536 000
    • Hussain Alizadeh · Principal investigator
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
    Szeged, 6725, Hungary
    Recruiting
    • · Contact+36704391136
    • Szabolcs Modok · Principal investigator
  • A.O.U.C. Policlinico di Bari
    Bari, 70124, Italy
    Recruiting
    • Francesco Albano · Principal investigator
  • Azienda Ospedaliero Universitaria S.Anna
    Cona, 44124, Italy
    Recruiting
    • · Contact+390532236977
    • Antonio Cuneo · Principal investigator
  • Azienda Ospedaliera Universitaria Careggi
    Florence, 50134, Italy
    Recruiting
    • · Contact00390557947958
    • alessandro sanna · Principal investigator
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
    Recruiting
    • Anna Maria Frustaci · Principal investigator
  • Azienda Ospedaliero Universitaria Maggiore della Carità
    Novara, 28100, Italy
    Recruiting
    • · Contact+39 03213733880
    • Riccardo Moia · Principal investigator
  • Azienda Ospedale - Università Padova
    Padova, 35128, Italy
    Recruiting
    • · Contact0498217809
    • Andrea Visentin · Principal investigator
  • Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO
    Palermo, 90146, Italy
    Recruiting
    • · Contact+390916802773
    • CATERINA PATTI · Principal investigator
  • AO Santa Maria della Misericordia
    Perugia, 06132, Italy
    Recruiting
    • · Contact+390755783990
    • PAOLO SPORTOLETTI · Principal investigator
  • AOU Policlinico Umberto I
    Roma, 00161, Italy
    Recruiting
    • · Contact0649974773
    • Maurizio Martelli · Principal investigator
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    Roma, 00168, Italy
    Recruiting
    • · Contact+39 0630157833
    • LUCA LAURENTI · Principal investigator
  • IN VIVO
    Bydgoszcz, 85-048, Poland
    Recruiting
    • Jaroslaw Czyz · Principal investigator
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
    Recruiting
    • · Contact+4832 3499751
    • Sebastian Grosicki · Principal investigator
  • Pratia MCM Krakow
    Krakow, 30-727, Poland
    Recruiting
    • · Contact+48 602338290
    • Wojciech Jurczak · Principal investigator
  • AIDPORT Sp. z o.o.
    Skórzewo, 60-185, Poland
    Recruiting
    • Michal Kwiatek · Principal investigator
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
    Wroclaw, 50-367, Poland
    Recruiting
    • · Contact501419272
    • Tomasz Wrobel · Principal investigator
  • Fundeni Clinical Institute
    Bucharest, 022328, Romania
    Recruiting
    • · Contact40212750500
    • Ana Maria Moldovianu · Principal investigator
  • Spitalul Clinic Colțea
    Bucharest, 030171, Romania
    Recruiting
    • · Contact0744150652
    • Gabriela Borsaru · Principal investigator
  • Institutul Oncologic Cluj
    Cluj-Napoca, 400015, Romania
    Recruiting
    • · Contact400741337480
    • Ciprian Tomuleasa · Principal investigator
  • Spitalul Clinic Municipal Filantropia Craiova
    Craiova, 200143, Romania
    Recruiting
    • · Contact0735439439
    • Ocroteala Luminita · Principal investigator
  • Institutul Regional de Oncologie
    Iași, 700483, Romania
    Recruiting
    • · Contact40722565781
    • Catalin Danaila · Principal investigator
  • Ovidius Clinical Hospital OCH
    Ovidiu, 905900, Romania
    Recruiting
    • · Contact0724877013
    • Andreea Caloian · Principal investigator
  • Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica
    Banská Bystrica, 975 17, Slovakia
    Recruiting
    • · Contact+421915803313
    • Anna Vallova · Principal investigator
  • Narodny onkologicky ustav
    Bratislava, 833 10, Slovakia
    Recruiting
    • Eva Mikuskova · Principal investigator
  • Univerzitna Nemocnica L. Pasteura Kosice
    Košice, 040 11, Slovakia
    Recruiting
    • · Contact+421556404410
    • Tomas Guman · Principal investigator
  • Univerzitna nemocnica Martin
    Martin, 036 59, Slovakia
    Recruiting
    • · Contact421902101385
    • Juraj Sokol · Principal investigator
  • Pusan National University Hospital
    Busan, 49241, South Korea
    Recruiting
    • · Contact+821089371258
    • Ho-Jin Shin · Principal investigator
  • Chonnam National University Hwasun Hospital
    Hwasun-gun, 58128, South Korea
    Recruiting
    • DEOK HWAN YANG · Principal investigator
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
    • Ja Min Byun · Principal investigator
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Recruiting
    • Seok Jin Kim · Principal investigator
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
    Recruiting
    • · Contact82222586056
    • Ki-Seong Eom · Principal investigator
  • The Catholic University of Korea, Yeouido St. Mary's Hospital
    Seoul, 07345, South Korea
    Recruiting
    • · Contact+821042324067
    • Youngwoo Jeon · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • · Contact+34 93 274 61 00 EXT 3806
    • Francisco Bosch Albareda · Principal investigator
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • · Contact932275400
    • Pablo Mozas · Principal investigator

Showing the first 100 of 129 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2028, 41 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's planned 41 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Jan 3, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed. 4 sites changed recruiting status (3 now active, not recruiting, 1 now completed)
Show 4 sites
  • Fakultní nemocnice Brno Bohunice · Brno, CzechiaRecruiting→Active, not recruiting
  • Fakultni nemocnice Hradec Kralove · Hradec Králové, CzechiaRecruiting→Active, not recruiting
  • Fakultni nemocnice Kralovske Vinohrady · Prague, CzechiaRecruiting→Completed
  • Vseobecna fakultni nemocnice v Praze · Prague, CzechiaRecruiting→Active, not recruiting
Show 2 removed
  • The West Clinic, PLLC dba West Cancer Center · Germantown, United States
  • Maidstone Hospital · Maidstone, United Kingdom
Nov 4, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Fakultní nemocnice Brno Bohunice · Brno, CzechiaContact removed •••3562Contact removed (no phone or email listed)
  • Fakultni nemocnice Hradec Kralove · Hradec Králové, CzechiaContact removed •••2886Contact removed (no phone or email listed)
  • Fakultni nemocnice Kralovske Vinohrady · Prague, CzechiaContact removed •••1110Contact removed (no phone or email listed)
  • Vseobecna fakultni nemocnice v Praze · Prague, CzechiaContact removed •••6845Contact removed (no phone or email listed)
  • A.O.U.C. Policlinico di Bari · Bari, ItalyContact •••3471→none listedContact removed (no phone or email listed)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites removed. 4 sites changed recruiting status (3 now active, not recruiting, 1 now completed)
    Show 4 sites
    • Fakultní nemocnice Brno Bohunice · Brno, CzechiaRecruiting→Active, not recruiting
    • Fakultni nemocnice Hradec Kralove · Hradec Králové, CzechiaRecruiting→Active, not recruiting
    • Fakultni nemocnice Kralovske Vinohrady · Prague, CzechiaRecruiting→Completed
    • Vseobecna fakultni nemocnice v Praze · Prague, CzechiaRecruiting→Active, not recruiting
    Show 2 removed
    • The West Clinic, PLLC dba West Cancer Center · Germantown, United States
    • Maidstone Hospital · Maidstone, United Kingdom
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Fakultní nemocnice Brno Bohunice · Brno, CzechiaContact removed •••3562Contact removed (no phone or email listed)
    • Fakultni nemocnice Hradec Kralove · Hradec Králové, CzechiaContact removed •••2886Contact removed (no phone or email listed)
    • Fakultni nemocnice Kralovske Vinohrady · Prague, CzechiaContact removed •••1110Contact removed (no phone or email listed)
    • Vseobecna fakultni nemocnice v Praze · Prague, CzechiaContact removed •••6845Contact removed (no phone or email listed)
    • A.O.U.C. Policlinico di Bari · Bari, ItalyContact •••3471→none listedContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06588478
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Jan 3, 2025
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion